Outils personnels

Vous êtes ici : Accueil / PHC Utique franco-tunisien / Projets en cours / Bacterial resistance roles in nosocomial infection and design of new inhibitors against ESBLS and MBLS as a strategy of therapy

Bacterial resistance roles in nosocomial infection and design of new inhibitors against ESBLS and MBLS as a strategy of therapy

PHC : Utique
Codes du projet : 17G0819 -- Campus N° 37027XL
Domaine : Biologie, médecine, santé
Intitulé : Bacterial resistance roles in nosocomial infection and design of new inhibitors against ESBLS and MBLS as a strategy of therapy
Porteur(s) : ROLAIN Jean-Marc, CHOUCHANI Chedly
Date de début : 01/01/2020
Date de fin : 31/12/2019

Bacterial drugs resistance is one of the great challenges for modern healthcare. In bacteria, extended-spectrum beta-lactamases (ESBLs) and metallo-beta-lactamase (MBL)-types have been rapidly spreading worldwide since the early 2000s. In Tunisia, like France, ESBLs and MBLs-producing bacteria are still frequent, but a 3-fold increase has been seen from 2004 to 2015. Nowadays the dissemination of Antibiotic-resistance in hospitals is already responsible for a considerable raise in morbidity and mortality
caused by infectious diseases.
The normal result of the abusive use of antibiotic in clinical therapy, have a result to increase the number of multidrug resistant strains, favourite also by the hygiene missing. We hypothesize that the dissemination of multidrug resistance to these antibiotics, including the lost resort antibiotics, may be at an earlier stage, providing the opportunity to study the progress of anthropogenicdriven dissemination and evolution firstly in Hospital environment. Also, unravelling these genes will certainly contribute to anticipate dissemination scenarios and to assess risks to human health. In this project, we propose to investigate bacterial resistance and their roles in nosocomial infection and we propose also as a strategy of therapy to design new inhibitors against ESBLs and MBLs..


The Hospitals have been confirmed as main reactors of dissemination and evolution of bacterial resistance to drugs. To achieve our aims, the research will be conducted in a number of Hospital area in Tunisia town and in similar Hospital area in France.
Resistance to extended-spectrum beta-lactams and carbapenems will be the target of our research since in Tunisia and in France the use of these last resort antibiotics is confined to hospitals and also because the research team has the experience and has already obtained preliminary data that fundamentals our proposal.


An integrative approach will be conducted to address central questions related to the occurrence, incidence, diversity and dispersion of bacterial resistance to drugs in hospital. Namely the correspondence between clinical and environmental genes and their occurrences in hospitals of molecular variants representing different evolution stages will be investigated. Also comparison between clinical and Hospital environments will provide insights into the dissemination of bacterial resistance and into dissemination-determining factors.
We are certain that the analysis of the overall results will contribute to elucidate the origins of drug resistance genes and their evolutionary routes and to anticipate potential risks to human health of the hospital environmental resistance.

Informations supplémentaires

Université Université Aix-Marseille (AMU)

Partenaire français

Laboratoire(s) ou unité(s) de recherche
Unité de recherche sur les maladies infectieuses et tropicales (URMITE)

Jean-Marc ROLAIN - URMITE - Marseille - Tél :0491324375 - Email :jean-marc.rolain@univ-amu.fr

Université de Tunis El-Manar

Partenaire tunisien

Laboratoire(s) ou unité(s) de recherche
Laboratoire de Microbiologie et Biomolécules Actives (LMBA)

Chedly CHOUCHANI - LMBA - Tunis - Tél :70860553 - Email :chdoula77@yahoo.fr